Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...

Rock Dept., author Niko Stratis writes about bagging groceries and what “Slide” taught her about the painful weight of first crushes.

A marriage of formal methods and LLMs seeks to harness the strengths of both.

For six months, I immersed myself only in books by authors who died by suicide. What began as a literary curiosity turned into an emotional narrowing that reshaped how reading felt. This reflection ...

Musk’s SpaceX-xAI deal reignites speculation of a Tesla merger with the combine. Invezz explores why analysts are forecasting it and what could lie in the way.

In NBC Select’s For What It’s Worth podcast, editors discuss the top shopping trends of 2026 across health, wellness, tech, fashion and travel.

Games Workshop is taking a deeper dive into the shiny new battletome of the Lumineth Realm-lords. Now we know even MORE about ...

Discover the world of Recursive Self-Improvement (RSI) in AI. From I.J. Good's intelligence explosion to modern self-healing code and clinical applications, explore who is developing it, how it works, ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

What works in controlled agentic AI demos often breaks down at scale, where integration, reliability, security, governance and performance expectations are far higher.

RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...